In the wake of the increase in Current Liabilities in the third quarter 2026, Quick Ratio fell to 1.95 below Xeris Biopharma Holdings Inc average.

Within Major Pharmaceutical Preparations industry 283 other companies have achieved higher Quick Ratio than Xeris Biopharma Holdings Inc in third quarter 2026. While Quick Ratio total ranking has improved so far during the Q3 2026 to 1351, from total ranking in the second quarter 2026 at 1756.

Explain Quick Ratio?
How much Cash & cash equivalents XERS�s has?
What are XERS�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/XERS/financial-strength

https://api.csimarket.com/api/v1/companies/XERS/fundamentals

https://api.csimarket.com/api/v1/companies/XERS/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

XERS Quick Ratio	(Sep 30 2026) Q3	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3
Y / Y Current Liabilities Change	15.73 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	186.21 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	1.95	Subscribe	Subscribe	Subscribe	Subscribe
XERS's Total Ranking	# 1351	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	19.19 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	7.67 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio third quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 284
Healthcare Sector	# 488
Overall Market	# 1351

Quick Ratio Statistics
High	Average	Low
17.91	4.51	0.61
(Dec 31 2017)		(Mar 31 2025)

Financial Statements
Xeris Biopharma Holdings Inc 's Current Liabilities	$ 134 Millions	Visit XERS's Balance sheet
Xeris Biopharma Holdings Inc 's Cash & cash equivalent	$ 262 Millions	Visit XERS's Balance sheet
Source of XERS's Sales		Visit XERS's Sales by Geography

Cumulative Xeris Biopharma Holdings Inc 's Quick Ratio

XERS's Quick Ratio for the trailling 12 Months

XERS Quick Ratio	(Sep 30 2026) 12 Months	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	16.86 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	159.29 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	1.53	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 1448	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	4 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	30.57 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to XERS Financial Strength Comparisons >> Go to Compare XERS Quick Ratio to its Competitors

On the trailing twelve months basis XERS Cash & cash equivalent more than doubled by 186.21 % in Q3 2026 year on year, faster than Current Liabilities, this led to increase in in Xeris Biopharma Holdings Inc 's Quick Ratio to 1.53, Quick Ratio remained below XERS average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 436 other companies have achieved higher Quick Ratio than Xeris Biopharma Holdings Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 3875 to 3949.

Explain Quick Ratio?
How much Cash & cash equivalents XERS�s has?
What are XERS�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 437
Healthcare Sector	# 893
Within the Market	#

trailing twelve months Quick Ratio Statistics
High	Average	Low
12.83	1.89	0.61
(Mar 31 2019)		(Dec 31 2023)

Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Sep 30 2026 MRQ Cash & cash equivalent	Sep 30 2026 MRQ Current Liabilities
Talphera Inc	5.29	$ 24.508 Millions	$ 4.630 Millions
Rocket Pharmaceuticals Inc	5.22	$ 279.470 Millions	$ 53.508 Millions
Aquestive Therapeutics Inc	5.22	$ 90.349 Millions	$ 17.299 Millions
Sionna Therapeutics Inc	5.11	$ 83.878 Millions	$ 16.420 Millions
Gain Therapeutics inc	4.94	$ 11.698 Millions	$ 2.369 Millions
Rani Therapeutics Holdings Inc	4.91	$ 45.288 Millions	$ 9.223 Millions
Abeona Therapeutics Inc	4.87	$ 134.941 Millions	$ 27.707 Millions
Shattuck Labs Inc	4.84	$ 61.758 Millions	$ 12.758 Millions
Mereo Biopharma Group Plc	4.75	$ 26.097 Millions	$ 5.494 Millions
Spruce Biosciences Inc	4.69	$ 87.691 Millions	$ 18.710 Millions
Diamedica Therapeutics Inc	4.68	$ 34.905 Millions	$ 7.454 Millions
Eledon Pharmaceuticals Inc	4.61	$ 69.672 Millions	$ 15.099 Millions
Septerna Inc	4.56	$ 478.601 Millions	$ 104.863 Millions
Atossa Therapeutics Inc	4.37	$ 20.574 Millions	$ 4.709 Millions
Adial Pharmaceuticals Inc	4.35	$ 22.000 Millions	$ 5.056 Millions
Neurogene Inc	4.35	$ 78.942 Millions	$ 18.163 Millions
Entrada Therapeutics Inc	4.34	$ 112.302 Millions	$ 25.863 Millions
Gyre Therapeutics Inc	4.34	$ 86.190 Millions	$ 19.874 Millions
Serina Therapeutics Inc	4.28	$ 19.403 Millions	$ 4.529 Millions
Cellectar Biosciences Inc	4.24	$ 24.582 Millions	$ 5.798 Millions
Bio Green Med Solution Inc	4.24	$ 3.454 Millions	$ 0.815 Millions
Foghorn Therapeutics Inc	4.19	$ 156.222 Millions	$ 37.315 Millions
Calcimedica Inc	4.12	$ 13.768 Millions	$ 3.339 Millions
Revelation Biosciences Inc	3.92	$ 9.122 Millions	$ 2.328 Millions
Tonix Pharmaceuticals Holding Corp	3.87	$ 162.793 Millions	$ 42.026 Millions
Lyell Immunopharma Inc	3.83	$ 177.106 Millions	$ 46.271 Millions
Rapport Therapeutics Inc	3.68	$ 74.754 Millions	$ 20.302 Millions
Seaport Therapeutics Inc	3.60	$ 61.552 Millions	$ 17.106 Millions
Xilio Therapeutics Inc	3.47	$ 122.182 Millions	$ 35.258 Millions
Corbus Pharmaceuticals Holdings Inc	3.30	$ 115.337 Millions	$ 34.967 Millions

Date modified: 2026-11-07T13:26:03+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.